Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy

AIM: Sorafenib is used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, hepatic arterial infusion chemotherapy (HAIC) has also gained acceptance, but only in Japan. We explored the role of body composition as a factor affecting the survival benefit of HAIC compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeki, Issei, Yamasaki, Takahiro, Maeda, Masaki, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6564002/
https://www.ncbi.nlm.nih.gov/pubmed/31194789
http://dx.doi.org/10.1371/journal.pone.0218136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6564002/
https://www.ncbi.nlm.nih.gov/pubmed/31194789
http://dx.doi.org/10.1371/journal.pone.0218136

Ejemplares similares